{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:23Z","timestamp":1792806143607,"version":"4.5.0"},"reference-count":75,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Molecular biological insights have led to a fundamental understanding of the underlying genomic mechanisms of nervous system disease. These findings have resulted in the identification of therapeutic genes that can be packaged in viral capsids for the treatment of a variety of neurological conditions, including neurodegenerative, metabolic, and enzyme deficiency disorders. Recent data have demonstrated that gene-carrying viral vectors (most often adeno-associated viruses) can be effectively distributed by convection-enhanced delivery (CED) in a safe, reliable, targeted, and homogeneous manner across the blood-brain barrier. Critically, these vectors can be monitored using real-time MRI of a co-infused surrogate tracer to accurately predict vector distribution and transgene expression at the perfused site. The unique properties of CED of adeno-associated virus vectors allow for cell-specific transgene manipulation of the infused anatomical site and\/or widespread interconnected sites via antero- and\/or retrograde transport. The authors review the convective properties of viral vectors, associated technology, and clinical applications.<\/jats:p>","DOI":"10.3171\/2020.4.jns20701","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T03:41:21Z","timestamp":1594352481000},"page":"1751-1763","source":"Crossref","is-referenced-by-count":48,"title":["Direct convective delivery of adeno-associated virus gene therapy for treatment of neurological disorders"],"prefix":"10.3171","volume":"134","author":[{"given":"Russell R.","family":"Lonser","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad S.","family":"Akhter","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142aw","family":"Zabek","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Br\u00f3dno Hospital, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bradley","family":"Elder","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystof S.","family":"Bankiewicz","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"6","key":"b1","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Bobo\n \nRH","year":"1994","unstructured":"Bobo\n \nRH\n\n, \n\nLaske\n \nDW\n\n, \n\nAkbasak\n \nA\n\n, \n\n\n \nConvection-enhanced delivery of macromolecules in the brain\n. \nProc Natl Acad Sci U S A\n. \n1994\n;\n91\n(\n6\n):\n2076\n\u2013\n2080\n.\n10.1073\/pnas.91.6.20768134351"},{"issue":"3","key":"b2","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3171\/2014.10.JNS14229","article-title":"Convection-enhanced delivery to the central nervous system","volume":"122","author":"Lonser\n \nRR","year":"2015","unstructured":"Lonser\n \nRR\n\n, \n\nSarntinoranont\n \nM\n\n, \n\nMorrison\n \nPF\n\n, \n\nOldfield\n \nEH\n\n\n. \nConvection-enhanced delivery to the central nervous system\n. \nJ Neurosurg\n. \n2015\n;\n122\n(\n3\n):\n697\n\u2013\n706\n.\n10.3171\/2014.10.JNS14229"},{"issue":"1","key":"b3","series-title":"Neurotherapeutics","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.nurt.2007.10.064","article-title":"Image-guided convection-enhanced delivery platform in the treatment of neurological diseases","volume":"5","author":"Fiandaca\n \nMS","year":"2008","unstructured":"Fiandaca\n \nMS\n\n, \n\nForsayeth\n \nJR\n\n, \n\nDickinson\n \nPJ\n\n, \n\nBankiewicz\n \nKS\n\n\n. \nImage-guided convection-enhanced delivery platform in the treatment of neurological diseases\n. \nNeurotherapeutics\n. \n2008\n;\n5\n(\n1\n):\n123\n\u2013\n127\n.\n1816449110.1016\/j.nurt.2007.10.064"},{"key":"b4","series-title":"Mol Ther Methods Clin Dev","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/mtm.2016.37","article-title":"Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington\u2019s disease","volume":"3","author":"Hadaczek\n \nP","year":"2016","unstructured":"Hadaczek\n \nP\n\n, \n\nStanek\n \nL\n\n, \n\nCiesielska\n \nA\n\n, \n\n\n \nWidespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington\u2019s disease\n. \nMol Ther Methods Clin Dev\n. \n2016\n;\n3\n:\n16037\n.\n10.1038\/mtm.2016.3727408903"},{"issue":"7","key":"b5","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1073\/pnas.0810682106","article-title":"Efficient gene therapy-based method for the delivery of therapeutics to primate cortex","volume":"106","author":"Kells\n \nAP","year":"2009","unstructured":"Kells\n \nAP\n\n, \n\nHadaczek\n \nP\n\n, \n\nYin\n \nD\n\n, \n\n\n \nEfficient gene therapy-based method for the delivery of therapeutics to primate cortex\n. \nProc Natl Acad Sci U S A\n. \n2009\n;\n106\n(\n7\n):\n2407\n\u2013\n2411\n.\n1919385710.1073\/pnas.0810682106"},{"issue":"5","key":"b6","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/mt.2010.248","article-title":"Anterograde axonal transport of AAV2-GDNF in rat basal ganglia","volume":"19","author":"Ciesielska\n \nA","year":"2011","unstructured":"Ciesielska\n \nA\n\n, \n\nMittermeyer\n \nG\n\n, \n\nHadaczek\n \nP\n\n, \n\n\n \nAnterograde axonal transport of AAV2-GDNF in rat basal ganglia\n. \nMol Ther\n. \n2011\n;\n19\n(\n5\n):\n922\n\u2013\n927\n.\n2110255910.1038\/mt.2010.248"},{"issue":"8","key":"b7","series-title":"Hum Gene Ther","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/hum.2013.189","article-title":"Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport","volume":"25","author":"Castle\n \nMJ","year":"2014","unstructured":"Castle\n \nMJ\n\n, \n\nGershenson\n \nZT\n\n, \n\nGiles\n \nAR\n\n, \n\n\n \nAdeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport\n. \nHum Gene Ther\n. \n2014\n;\n25\n(\n8\n):\n705\n\u2013\n720\n.\n10.1089\/hum.2013.18924694006"},{"issue":"5","key":"b8","series-title":"Hum Gene Ther","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/hum.2008.201","article-title":"Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys","volume":"20","author":"Eberling\n \nJL","year":"2009","unstructured":"Eberling\n \nJL\n\n, \n\nKells\n \nAP\n\n, \n\nPivirotto\n \nP\n\n, \n\n\n \nFunctional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys\n. \nHum Gene Ther\n. \n2009\n;\n20\n(\n5\n):\n511\n\u2013\n518\n.\n10.1089\/hum.2008.20119254173"},{"issue":"7","key":"b9","series-title":"Adv Drug Deliv Rev","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.addr.2011.10.005","article-title":"Guided delivery of adeno-associated viral vectors into the primate brain","volume":"64","author":"Salegio\n \nEA","year":"2012","unstructured":"Salegio\n \nEA\n\n, \n\nSamaranch\n \nL\n\n, \n\nKells\n \nAP\n\n, \n\n\n \nGuided delivery of adeno-associated viral vectors into the primate brain\n. \nAdv Drug Deliv Rev\n. \n2012\n;\n64\n(\n7\n):\n598\n\u2013\n604\n.\n2203690610.1016\/j.addr.2011.10.005"},{"issue":"3","key":"b10","series-title":"Gene Ther","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/gt.2012.27","article-title":"Axonal transport of adeno-associated viral vectors is serotype-dependent","volume":"20","author":"Salegio\n \nEA","year":"2013","unstructured":"Salegio\n \nEA\n\n, \n\nSamaranch\n \nL\n\n, \n\nKells\n \nAP\n\n, \n\n\n \nAxonal transport of adeno-associated viral vectors is serotype-dependent\n. \nGene Ther\n. \n2013\n;\n20\n(\n3\n):\n348\n\u2013\n352\n.\n10.1038\/gt.2012.2722418061"},{"issue":"506","key":"b11","series-title":"Sci Transl Med","doi-asserted-by":"publisher","first-page":"eaat3738","DOI":"10.1126\/scitranslmed.aat3738","article-title":"Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A","volume":"11","author":"Samaranch\n \nL","year":"2019","unstructured":"Samaranch\n \nL\n\n, \n\nP\u00e9rez-Ca\u00f1am\u00e1s\n \nA\n\n, \n\nSoto-Huelin\n \nB\n\n, \n\n\n \nAdeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A\n. \nSci Transl Med\n. \n2019\n;\n11\n(\n506\n):\neaat3738\n.\n3143475410.1126\/scitranslmed.aat3738"},{"issue":"10","key":"b12","series-title":"Nat Rev Drug Discov","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd.2018.158","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman\n \nBE","year":"2018","unstructured":"Deverman\n \nBE\n\n, \n\nRavina\n \nBM\n\n, \n\nBankiewicz\n \nKS\n\n, \n\n\n \nGene therapy for neurological disorders: progress and prospects\n. \nNat Rev Drug Discov\n. \n2018\n;\n17\n(\n10\n):\n767\n.\n10.1038\/nrd.2018.15830206384"},{"issue":"5","key":"b13","series-title":"Ann Neurol","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","article-title":"Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease","volume":"85","author":"Christine\n \nCW","year":"2019","unstructured":"Christine\n \nCW\n\n, \n\nBankiewicz\n \nKS\n\n, \n\nVan Laar\n \nAD\n\n, \n\n\n \nMagnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease\n. \nAnn Neurol\n. \n2019\n;\n85\n(\n5\n):\n704\n\u2013\n714\n.\n10.1002\/ana.2545030802998"},{"issue":"8","key":"b14","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/mt.2010.114","article-title":"Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors","volume":"18","author":"Su\n \nX","year":"2010","unstructured":"Su\n \nX\n\n, \n\nKells\n \nAP\n\n, \n\nSalegio\n \nEA\n\n, \n\n\n \nReal-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors\n. \nMol Ther\n. \n2010\n;\n18\n(\n8\n):\n1490\n\u2013\n1495\n. \nPublished correction in Mol Ther. 2012;20(2):468\n.\n10.1038\/mt.2010.11420551915"},{"issue":"4","key":"b15","series-title":"Neurosurg Clin N Am","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.nec.2017.05.012","article-title":"Imaging of convective drug delivery in the nervous system","volume":"28","author":"Lonser\n \nRR","year":"2017","unstructured":"Lonser\n \nRR\n\n\n. \nImaging of convective drug delivery in the nervous system\n. \nNeurosurg Clin N Am\n. \n2017\n;\n28\n(\n4\n):\n615\n\u2013\n622\n.\n10.1016\/j.nec.2017.05.01228917289"},{"issue":"1","key":"b16","series-title":"Neuron","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuron.2019.03.020","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"102","author":"Hudry\n \nE","year":"2019","unstructured":"Hudry\n \nE\n\n, \n\nVandenberghe\n \nLH\n\n\n. \nTherapeutic AAV gene transfer to the nervous system: a clinical reality\n. \nNeuron\n. \n2019\n;\n102\n(\n1\n):\n263\n.\n10.1016\/j.neuron.2019.03.020"},{"issue":"7","key":"b17","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/mt.2008.103","article-title":"Recombinant adeno-associated virus transduction and integration","volume":"16","author":"Schultz\n \nBR","year":"2008","unstructured":"Schultz\n \nBR\n\n, \n\nChamberlain\n \nJS\n\n\n. \nRecombinant adeno-associated virus transduction and integration\n. \nMol Ther\n. \n2008\n;\n16\n(\n7\n):\n1189\n\u2013\n1199\n.\n10.1038\/mt.2008.10318500252"},{"issue":"5","key":"b18","series-title":"Nat Rev Drug Discov","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang\n \nD","year":"2019","unstructured":"Wang\n \nD\n\n, \n\nTai\n \nPWL\n\n, \n\nGao\n \nG\n\n\n. \nAdeno-associated virus vector as a platform for gene therapy delivery\n. \nNat Rev Drug Discov\n. \n2019\n;\n18\n(\n5\n):\n358\n\u2013\n378\n.\n10.1038\/s41573-019-0012-930710128"},{"key":"b19","series-title":"Methods Mol Biol","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-4939-3271-9_10","article-title":"Controlling AAV tropism in the nervous system with natural and engineered capsids","volume":"1382","author":"Castle\n \nMJ","year":"2016","unstructured":"Castle\n \nMJ\n\n, \n\nTurunen\n \nHT\n\n, \n\nVandenberghe\n \nLH\n\n, \n\nWolfe\n \nJH\n\n\n. \nControlling AAV tropism in the nervous system with natural and engineered capsids\n. \nMethods Mol Biol\n. \n2016\n;\n1382\n:\n133\n\u2013\n149\n.\n2661158410.1007\/978-1-4939-3271-9_10"},{"issue":"34","key":"b20","series-title":"Oncogene","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1038\/s41388-019-0870-y","article-title":"Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance","volume":"38","author":"Totsch\n \nSK","year":"2019","unstructured":"Totsch\n \nSK\n\n, \n\nSchlappi\n \nC\n\n, \n\nKang\n \nKD\n\n, \n\n\n \nOncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance\n. \nOncogene\n. \n2019\n;\n38\n(\n34\n):\n6159\n\u2013\n6171\n.\n3128936110.1038\/s41388-019-0870-y"},{"issue":"6","key":"b21","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ymthe.2004.09.011","article-title":"Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective","volume":"10","author":"Carter\n \nBJ","year":"2004","unstructured":"Carter\n \nBJ\n\n\n. \nAdeno-associated virus and the development of adeno-associated virus vectors: a historical perspective\n. \nMol Ther\n. \n2004\n;\n10\n(\n6\n):\n981\n\u2013\n989\n.\n10.1016\/j.ymthe.2004.09.01115564130"},{"issue":"3","key":"b22","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera\n \nHC","year":"2020","unstructured":"Verdera\n \nHC\n\n, \n\nKuranda\n \nK\n\n, \n\nMingozzi\n \nF\n\n\n. \nAAV vector immunogenicity in humans: a long journey to successful gene transfer\n. \nMol Ther\n. \n2020\n;\n28\n(\n3\n):\n723\n\u2013\n746\n.\n10.1016\/j.ymthe.2019.12.01031972133"},{"issue":"4","key":"b23","series-title":"Clin Microbiol Rev","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya\n \nS","year":"2008","unstructured":"Daya\n \nS\n\n, \n\nBerns\n \nKI\n\n\n. \nGene therapy using adeno-associated virus vectors\n. \nClin Microbiol Rev\n. \n2008\n;\n21\n(\n4\n):\n583\n\u2013\n593\n.\n10.1128\/CMR.00008-0818854481"},{"issue":"1","key":"b24","series-title":"J Pharmacol Exp Ther","first-page":"73","article-title":"Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion","volume":"195","author":"Blasberg\n \nRG","year":"1975","unstructured":"Blasberg\n \nRG\n\n, \n\nPatlak\n \nC\n\n, \n\nFenstermacher\n \nJD\n\n\n. \nIntrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion\n. \nJ Pharmacol Exp Ther\n. \n1975\n;\n195\n(\n1\n):\n73\n\u2013\n83\n.\n810575"},{"issue":"1","key":"b25","series-title":"J Cereb Blood Flow Metab","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/jcbfm.2012.153","article-title":"Immunologic privilege in the central nervous system and the blood-brain barrier","volume":"33","author":"Muldoon\n \nLL","year":"2013","unstructured":"Muldoon\n \nLL\n\n, \n\nAlvarez\n \nJI\n\n, \n\nBegley\n \nDJ\n\n, \n\n\n \nImmunologic privilege in the central nervous system and the blood-brain barrier\n. \nJ Cereb Blood Flow Metab\n. \n2013\n;\n33\n(\n1\n):\n13\n\u2013\n21\n.\n2307274910.1038\/jcbfm.2012.153"},{"issue":"4976","key":"b26","series-title":"Science","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1126\/science.2218494","article-title":"New methods of drug delivery","volume":"249","author":"Langer\n \nR.","year":"1990","unstructured":"Langer\n \nR.\n\n\n \nNew methods of drug delivery\n. \nScience\n. \n1990\n;\n249\n(\n4976\n):\n1527\n\u2013\n1533\n.\n221849410.1126\/science.2218494"},{"issue":"7","key":"b27","series-title":"J Cereb Blood Flow Metab","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/00004647-199707000-00001","article-title":"Drug delivery to the brain","volume":"17","author":"Pardridge\n \nWM","year":"1997","unstructured":"Pardridge\n \nWM\n\n\n. \nDrug delivery to the brain\n. \nJ Cereb Blood Flow Metab\n. \n1997\n;\n17\n(\n7\n):\n713\n\u2013\n731\n.\n10.1097\/00004647-199707000-00001"},{"issue":"3","key":"b28","series-title":"J Pharmacol Exp Ther","first-page":"1647","article-title":"Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants","volume":"275","author":"Strasser\n \nJF","year":"1995","unstructured":"Strasser\n \nJF\n\n, \n\nFung\n \nLK\n\n, \n\nEller\n \nS\n\n, \n\n\n \nDistribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants\n. \nJ Pharmacol Exp Ther\n. \n1995\n;\n275\n(\n3\n):\n1647\n\u2013\n1655\n.\n8531140"},{"key":"b29","series-title":"Nervous System Drug Delivery: Principles and Practice","author":"Lonser\n \nRR","year":"2019","unstructured":"Lonser\n \nRR\n\n, \n\nSarntinoranont\n \nM\n\n, \n\nBankiewicz\n \nK\n\n\n. \nNervous System Drug Delivery: Principles and Practice\n. \nElsevier\n; \n2019\n."},{"key":"b30","series-title":"J Control Release","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jconrel.2016.02.034","article-title":"AAV viral vector delivery to the brain by shape-conforming MR-guided infusions","volume":"240","author":"Bankiewicz\n \nKS","year":"2016","unstructured":"Bankiewicz\n \nKS\n\n, \n\nSudhakar\n \nV\n\n, \n\nSamaranch\n \nL\n\n, \n\n\n \nAAV viral vector delivery to the brain by shape-conforming MR-guided infusions\n. \nJ Control Release\n. \n2016\n;\n240\n:\n434\n\u2013\n442\n.\n10.1016\/j.jconrel.2016.02.034"},{"issue":"suppl 1","key":"b31","series-title":"Neuroimage","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1016\/j.neuroimage.2010.01.023","article-title":"Image-guided convection-enhanced delivery of GDNF protein into monkey putamen","volume":"54","author":"Gimenez\n \nF","year":"2011","unstructured":"Gimenez\n \nF\n\n, \n\nKrauze\n \nMT\n\n, \n\nValles\n \nF\n\n, \n\n\n \nImage-guided convection-enhanced delivery of GDNF protein into monkey putamen\n. \nNeuroimage\n. \n2011\n;\n54\n(\nsuppl 1\n):\nS189\n\u2013\nS195\n.\n10.1016\/j.neuroimage.2010.01.02320080195"},{"issue":"2","key":"b32","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3171\/jns.1999.90.2.0315","article-title":"Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time","volume":"90","author":"Chen\n \nMY","year":"1999","unstructured":"Chen\n \nMY\n\n, \n\nLonser\n \nRR\n\n, \n\nMorrison\n \nPF\n\n, \n\n\n \nVariables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time\n. \nJ Neurosurg\n. \n1999\n;\n90\n(\n2\n):\n315\n\u2013\n320\n.\n10.3171\/jns.1999.90.2.0315"},{"issue":"3","key":"b33","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3171\/JNS-07\/09\/0560","article-title":"Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles","volume":"107","author":"Szerlip\n \nNJ","year":"2007","unstructured":"Szerlip\n \nNJ\n\n, \n\nWalbridge\n \nS\n\n, \n\nYang\n \nL\n\n, \n\n\n \nReal-time imaging of convection-enhanced delivery of viruses and virus-sized particles\n. \nJ Neurosurg\n. \n2007\n;\n107\n(\n3\n):\n560\n\u2013\n567\n.\n10.3171\/JNS-07\/09\/056017886556"},{"issue":"6","key":"b34","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/mt.2011.11","article-title":"Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson\u2019s disease","volume":"19","author":"Richardson\n \nRM","year":"2011","unstructured":"Richardson\n \nRM\n\n, \n\nKells\n \nAP\n\n, \n\nRosenbluth\n \nKH\n\n, \n\n\n \nInterventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson\u2019s disease\n. \nMol Ther\n. \n2011\n;\n19\n(\n6\n):\n1048\n\u2013\n1057\n.\n10.1038\/mt.2011.1121343917"},{"issue":"3","key":"b35","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/mt.2013.237","article-title":"Long-distance axonal transport of AAV9 is driven by dynein and kinesin-2 and is trafficked in a highly motile Rab7-positive compartment","volume":"22","author":"Castle\n \nMJ","year":"2014","unstructured":"Castle\n \nMJ\n\n, \n\nPerlson\n \nE\n\n, \n\nHolzbaur\n \nEL\n\n, \n\nWolfe\n \nJH\n\n\n. \nLong-distance axonal transport of AAV9 is driven by dynein and kinesin-2 and is trafficked in a highly motile Rab7-positive compartment\n. \nMol Ther\n. \n2014\n;\n22\n(\n3\n):\n554\n\u2013\n566\n.\n10.1038\/mt.2013.237"},{"issue":"1","key":"b36","series-title":"Exp Neurol","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.expneurol.2005.07.009","article-title":"Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen","volume":"196","author":"Krauze\n \nMT","year":"2005","unstructured":"Krauze\n \nMT\n\n, \n\nSaito\n \nR\n\n, \n\nNoble\n \nC\n\n, \n\n\n \nEffects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen\n. \nExp Neurol\n. \n2005\n;\n196\n(\n1\n):\n104\n\u2013\n111\n.\n1610941010.1016\/j.expneurol.2005.07.009"},{"key":"b37","series-title":"J Neurosurg","article-title":"Infuse-as-you-go convective delivery to enhance coverage of elongated brain targets: technical note","author":"Sudhakar\n \nV","unstructured":"Sudhakar\n \nV\n\n, \n\nNaidoo\n \nJ\n\n, \n\nSamaranch\n \nL\n\n, \n\n\n \nInfuse-as-you-go convective delivery to enhance coverage of elongated brain targets: technical note\n. \nJ Neurosurg\n. \nPublished online July 12, 2019. doi:10.3171\/2019.4.JNS19826\n31299656"},{"issue":"5","key":"b38","series-title":"Hum Gene Ther","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1089\/hum.2013.005","article-title":"Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates","volume":"24","author":"Samaranch\n \nL","year":"2013","unstructured":"Samaranch\n \nL\n\n, \n\nSalegio\n \nEA\n\n, \n\nSan Sebastian\n \nW\n\n, \n\n\n \nStrong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates\n. \nHum Gene Ther\n. \n2013\n;\n24\n(\n5\n):\n526\n\u2013\n532\n.\n2351747310.1089\/hum.2013.005"},{"issue":"Pt 3","key":"b39","series-title":"J Anat","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1469-7580.1997.19130337.x","article-title":"Perivascular spaces in the basal ganglia of the human brain: their relationship to lacunes","volume":"191","author":"Pollock\n \nH","year":"1997","unstructured":"Pollock\n \nH\n\n, \n\nHutchings\n \nM\n\n, \n\nWeller\n \nRO\n\n, \n\nZhang\n \nET\n\n\n. \nPerivascular spaces in the basal ganglia of the human brain: their relationship to lacunes\n. \nJ Anat\n. \n1997\n;\n191\n(\nPt 3\n):\n337\n\u2013\n346\n.\n10.1046\/j.1469-7580.1997.19130337.x9418990"},{"issue":"1","key":"b40","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymthe.2006.02.018","article-title":"The \u201cperivascular pump\u201d driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain","volume":"14","author":"Hadaczek\n \nP","year":"2006","unstructured":"Hadaczek\n \nP\n\n, \n\nYamashita\n \nY\n\n, \n\nMirek\n \nH\n\n, \n\n\n \nThe \u201cperivascular pump\u201d driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain\n. \nMol Ther\n. \n2006\n;\n14\n(\n1\n):\n69\n\u2013\n78\n.\n1665080710.1016\/j.ymthe.2006.02.018"},{"issue":"3","key":"b41","series-title":"Stereotact Funct Neurosurg","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000323544","article-title":"Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain","volume":"89","author":"Richardson\n \nRM","year":"2011","unstructured":"Richardson\n \nRM\n\n, \n\nKells\n \nAP\n\n, \n\nMartin\n \nAJ\n\n, \n\n\n \nNovel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain\n. \nStereotact Funct Neurosurg\n. \n2011\n;\n89\n(\n3\n):\n141\n\u2013\n151\n.\n10.1159\/00032354421494065"},{"issue":"7","key":"b42","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/mds.27724","article-title":"Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease","volume":"34","author":"Heiss\n \nJD","year":"2019","unstructured":"Heiss\n \nJD\n\n, \n\nLungu\n \nC\n\n, \n\nHammoud\n \nDA\n\n, \n\n\n \nTrial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease\n. \nMov Disord\n. \n2019\n;\n34\n(\n7\n):\n1073\n\u2013\n1078\n.\n10.1002\/mds.2772431145831"},{"issue":"3","key":"b43","series-title":"J Neurosurg Pediatr","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3171\/2013.11.PEDS136","article-title":"Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas","volume":"13","author":"Chittiboina\n \nP","year":"2014","unstructured":"Chittiboina\n \nP\n\n, \n\nHeiss\n \nJD\n\n, \n\nWarren\n \nKE\n\n, \n\nLonser\n \nRR\n\n\n. \nMagnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas\n. \nJ Neurosurg Pediatr\n. \n2014\n;\n13\n(\n3\n):\n276\n\u2013\n282\n.\n10.3171\/2013.11.PEDS13624410126"},{"issue":"suppl 2","key":"b44","series-title":"J Nucl Med","doi-asserted-by":"publisher","first-page":"164S","DOI":"10.2967\/jnumed.107.045955","article-title":"Molecular-genetic imaging based on reporter gene expression","volume":"49","author":"Kang\n \nJH","year":"2008","unstructured":"Kang\n \nJH\n\n, \n\nChung\n \nJK\n\n\n. \nMolecular-genetic imaging based on reporter gene expression\n. \nJ Nucl Med\n. \n2008\n;\n49\n(\nsuppl 2\n):\n164S\n\u2013\n179S\n.\n10.2967\/jnumed.107.04595518523072"},{"issue":"3","key":"b45","series-title":"Hum Gene Ther","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1089\/hum.2008.151","article-title":"Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response","volume":"20","author":"Hadaczek\n \nP","year":"2009","unstructured":"Hadaczek\n \nP\n\n, \n\nForsayeth\n \nJ\n\n, \n\nMirek\n \nH\n\n, \n\n\n \nTransduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response\n. \nHum Gene Ther\n. \n2009\n;\n20\n(\n3\n):\n225\n\u2013\n237\n.\n1929260410.1089\/hum.2008.151"},{"issue":"4","key":"b46","series-title":"Gene Ther","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/gt.2015.87","article-title":"Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response","volume":"23","author":"Samaranch\n \nL","year":"2016","unstructured":"Samaranch\n \nL\n\n, \n\nHadaczek\n \nP\n\n, \n\nKells\n \nAP\n\n, \n\n\n \nSlow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response\n. \nGene Ther\n. \n2016\n;\n23\n(\n4\n):\n393\n\u2013\n398\n.\n10.1038\/gt.2015.8726510688"},{"issue":"2","key":"b47","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/mt.2013.266","article-title":"AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction","volume":"22","author":"Samaranch\n \nL","year":"2014","unstructured":"Samaranch\n \nL\n\n, \n\nSebastian\n \nWS\n\n, \n\nKells\n \nAP\n\n, \n\n\n \nAAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction\n. \nMol Ther\n. \n2014\n;\n22\n(\n2\n):\n329\n\u2013\n337\n.\n2441908110.1038\/mt.2013.266"},{"issue":"5","key":"b48","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3171\/jns.2005.103.5.0923","article-title":"Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents","volume":"103","author":"Krauze\n \nMT","year":"2005","unstructured":"Krauze\n \nMT\n\n, \n\nSaito\n \nR\n\n, \n\nNoble\n \nC\n\n, \n\n\n \nReflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents\n. \nJ Neurosurg\n. \n2005\n;\n103\n(\n5\n):\n923\n\u2013\n929\n.\n10.3171\/jns.2005.103.5.092316304999"},{"issue":"5","key":"b49","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3171\/2014.11.JNS131888","article-title":"Accuracy of direct magnetic resonance imaging-guided placement of drug infusion cannulae","volume":"122","author":"Chittiboina\n \nP","year":"2015","unstructured":"Chittiboina\n \nP\n\n, \n\nHeiss\n \nJD\n\n, \n\nLonser\n \nRR\n\n\n. \nAccuracy of direct magnetic resonance imaging-guided placement of drug infusion cannulae\n. \nJ Neurosurg\n. \n2015\n;\n122\n(\n5\n):\n1173\n\u2013\n1179\n.\n10.3171\/2014.11.JNS13188825594325"},{"issue":"4","key":"b50","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3171\/2015.5.JNS1589","article-title":"Real-time magnetic resonance imaging-guided frameless stereotactic brain biopsy: technical note","volume":"124","author":"Mohyeldin\n \nA","year":"2016","unstructured":"Mohyeldin\n \nA\n\n, \n\nLonser\n \nRR\n\n, \n\nElder\n \nJB\n\n\n. \nReal-time magnetic resonance imaging-guided frameless stereotactic brain biopsy: technical note\n. \nJ Neurosurg\n. \n2016\n;\n124\n(\n4\n):\n1039\n\u2013\n1046\n.\n10.3171\/2015.5.JNS158926495951"},{"issue":"6","key":"b51","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3171\/jns.1995.82.6.1021","article-title":"Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion","volume":"82","author":"Lieberman\n \nDM","year":"1995","unstructured":"Lieberman\n \nDM\n\n, \n\nLaske\n \nDW\n\n, \n\nMorrison\n \nPF\n\n, \n\n\n \nConvection-enhanced distribution of large molecules in gray matter during interstitial drug infusion\n. \nJ Neurosurg\n. \n1995\n;\n82\n(\n6\n):\n1021\n\u2013\n1029\n.\n10.3171\/jns.1995.82.6.10217539062"},{"issue":"2","key":"b52","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3171\/2018.10.JNS182169","article-title":"Development of a novel frameless skull-mounted ball-joint guide array for use in image-guided neurosurgery","volume":"132","author":"Sudhakar\n \nV","year":"2020","unstructured":"Sudhakar\n \nV\n\n, \n\nMahmoodi\n \nA\n\n, \n\nBringas\n \nJR\n\n, \n\n\n \nDevelopment of a novel frameless skull-mounted ball-joint guide array for use in image-guided neurosurgery\n. \nJ Neurosurg\n. \n2020\n;\n132\n(\n2\n):\n595\n\u2013\n604\n.\n10.3171\/2018.10.JNS182169"},{"issue":"3","key":"b53","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog\n \nJE","year":"2001","unstructured":"Ahlskog\n \nJE\n\n, \n\nMuenter\n \nMD\n\n\n. \nFrequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature\n. \nMov Disord\n. \n2001\n;\n16\n(\n3\n):\n448\n\u2013\n458\n.\n10.1002\/mds.109011391738"},{"issue":"3","key":"b54","series-title":"Lancet Neurol","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","article-title":"Impulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update","volume":"16","author":"Voon\n \nV","year":"2017","unstructured":"Voon\n \nV\n\n, \n\nNapier\n \nTC\n\n, \n\nFrank\n \nMJ\n\n, \n\n\n \nImpulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update\n. \nLancet Neurol\n. \n2017\n;\n16\n(\n3\n):\n238\n\u2013\n250\n.\n2822989510.1016\/S1474-4422(17)30004-2"},{"issue":"3\u20134","key":"b55","series-title":"J Pharmacokinet Pharmacodyn","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10928-005-0055-x","article-title":"Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson\u2019s disease","volume":"32","author":"Chan\n \nPL","year":"2005","unstructured":"Chan\n \nPL\n\n, \n\nNutt\n \nJG\n\n, \n\nHolford\n \nNH\n\n\n. \nPharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson\u2019s disease\n. \nJ Pharmacokinet Pharmacodyn\n. \n2005\n;\n32\n(\n3\u20134\n):\n459\n\u2013\n484\n.\n10.1007\/s10928-005-0055-x16320101"},{"issue":"2","key":"b56","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e0169965","DOI":"10.1371\/journal.pone.0169965","article-title":"Depletion of AADC activity in caudate nucleus and putamen of Parkinson\u2019s disease patients; implications for ongoing AAV2-AADC gene therapy trial","volume":"12","author":"Ciesielska\n \nA","year":"2017","unstructured":"Ciesielska\n \nA\n\n, \n\nSamaranch\n \nL\n\n, \n\nSan Sebastian\n \nW\n\n, \n\n\n \nDepletion of AADC activity in caudate nucleus and putamen of Parkinson\u2019s disease patients; implications for ongoing AAV2-AADC gene therapy trial\n. \nPLoS One\n. \n2017\n;\n12\n(\n2\n):\ne0169965\n.\n10.1371\/journal.pone.016996528166239"},{"issue":"12","key":"b57","series-title":"Hum Gene Ther","first-page":"1589","article-title":"Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation","volume":"12","author":"During\n \nMJ","year":"2001","unstructured":"During\n \nMJ\n\n, \n\nKaplitt\n \nMG\n\n, \n\nStern\n \nMB\n\n, \n\nEidelberg\n \nD\n\n\n. \nSubthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation\n. \nHum Gene Ther\n. \n2001\n;\n12\n(\n12\n):\n1589\n\u2013\n1591\n.\n11529246"},{"issue":"9579","key":"b58","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial","volume":"369","author":"Kaplitt\n \nMG","year":"2007","unstructured":"Kaplitt\n \nMG\n\n, \n\nFeigin\n \nA\n\n, \n\nTang\n \nC\n\n, \n\n\n \nSafety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial\n. \nLancet\n. \n2007\n;\n369\n(\n9579\n):\n2097\n\u2013\n2105\n.\n1758630510.1016\/S0140-6736(07)60982-9"},{"issue":"7","key":"b59","series-title":"JCI Insight","doi-asserted-by":"publisher","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","article-title":"Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease","volume":"2","author":"Niethammer\n \nM","year":"2017","unstructured":"Niethammer\n \nM\n\n, \n\nTang\n \nCC\n\n, \n\nLeWitt\n \nPA\n\n, \n\n\n \nLong-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease\n. \nJCI Insight\n. \n2017\n;\n2\n(\n7\n):\ne90133\n.\n10.1172\/jci.insight.9013328405611"},{"issue":"469","key":"b60","series-title":"Sci Transl Med","doi-asserted-by":"publisher","first-page":"eaau0713","DOI":"10.1126\/scitranslmed.aau0713","article-title":"Gene therapy reduces Parkinson\u2019s disease symptoms by reorganizing functional brain connectivity","volume":"10","author":"Niethammer\n \nM","year":"2018","unstructured":"Niethammer\n \nM\n\n, \n\nTang\n \nCC\n\n, \n\nVo\n \nA\n\n, \n\n\n \nGene therapy reduces Parkinson\u2019s disease symptoms by reorganizing functional brain connectivity\n. \nSci Transl Med\n. \n2018\n;\n10\n(\n469\n):\neaau0713\n.\n3048724810.1126\/scitranslmed.aau0713"},{"issue":"6","key":"b61","series-title":"Hum Mol Genet","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/hmg\/ddq558","article-title":"SOX9 controls epithelial branching by activating RET effector genes during kidney development","volume":"20","author":"Reginensi\n \nA","year":"2011","unstructured":"Reginensi\n \nA\n\n, \n\nClarkson\n \nM\n\n, \n\nNeirijnck\n \nY\n\n, \n\n\n \nSOX9 controls epithelial branching by activating RET effector genes during kidney development\n. \nHum Mol Genet\n. \n2011\n;\n20\n(\n6\n):\n1143\n\u2013\n1153\n.\n10.1093\/hmg\/ddq55821212101"},{"issue":"2","key":"b62","series-title":"Cell Tissue Res","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s004410050867","article-title":"GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro","volume":"289","author":"Clarkson\n \nED","year":"1997","unstructured":"Clarkson\n \nED\n\n, \n\nZawada\n \nWM\n\n, \n\nFreed\n \nCR\n\n\n. \nGDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro\n. \nCell Tissue Res\n. \n1997\n;\n289\n(\n2\n):\n207\n\u2013\n210\n.\n10.1007\/s0044100508679211823"},{"issue":"1","key":"b63","series-title":"Neuroreport","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00001756-199512000-00035","article-title":"GDNF reduces apoptosis in dopaminergic neurons in vitro","volume":"7","author":"Clarkson\n \nED","year":"1995","unstructured":"Clarkson\n \nED\n\n, \n\nZawada\n \nWM\n\n, \n\nFreed\n \nCR\n\n\n. \nGDNF reduces apoptosis in dopaminergic neurons in vitro\n. \nNeuroreport\n. \n1995\n;\n7\n(\n1\n):\n145\n\u2013\n149\n.\n10.1097\/00001756-199512000-000358742438"},{"issue":"5111","key":"b64","series-title":"Science","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin\n \nLF","year":"1993","unstructured":"Lin\n \nLF\n\n, \n\nDoherty\n \nDH\n\n, \n\nLile\n \nJD\n\n, \n\n\n \nGDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons\n. \nScience\n. \n1993\n;\n260\n(\n5111\n):\n1130\n\u2013\n1132\n.\n849355710.1126\/science.8493557"},{"issue":"6571","key":"b65","series-title":"Nature","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/380252a0","article-title":"Functional recovery in parkinsonian monkeys treated with GDNF","volume":"380","author":"Gash\n \nDM","year":"1996","unstructured":"Gash\n \nDM\n\n, \n\nZhang\n \nZ\n\n, \n\nOvadia\n \nA\n\n, \n\n\n \nFunctional recovery in parkinsonian monkeys treated with GDNF\n. \nNature\n. \n1996\n;\n380\n(\n6571\n):\n252\n\u2013\n255\n.\n10.1038\/380252a08637574"},{"issue":"4","key":"b66","series-title":"J Neurosci","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1523\/JNEUROSCI.4421-04.2005","article-title":"Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson\u2019s disease","volume":"25","author":"Eslamboli\n \nA","year":"2005","unstructured":"Eslamboli\n \nA\n\n, \n\nGeorgievska\n \nB\n\n, \n\nRidley\n \nRM\n\n, \n\n\n \nContinuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson\u2019s disease\n. \nJ Neurosci\n. \n2005\n;\n25\n(\n4\n):\n769\n\u2013\n777\n.\n10.1523\/JNEUROSCI.4421-04.2005"},{"issue":"28","key":"b67","series-title":"J Neurosci","doi-asserted-by":"publisher","first-page":"9567","DOI":"10.1523\/JNEUROSCI.0942-10.2010","article-title":"Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF","volume":"30","author":"Kells\n \nAP","year":"2010","unstructured":"Kells\n \nAP\n\n, \n\nEberling\n \nJ\n\n, \n\nSu\n \nX\n\n, \n\n\n \nRegeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF\n. \nJ Neurosci\n. \n2010\n;\n30\n(\n28\n):\n9567\n\u2013\n9577\n.\n2063118510.1523\/JNEUROSCI.0942-10.2010"},{"issue":"5","key":"b68","series-title":"Hum Gene Ther","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/hum.2008.137","article-title":"Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys","volume":"20","author":"Johnston\n \nLC","year":"2009","unstructured":"Johnston\n \nLC\n\n, \n\nEberling\n \nJ\n\n, \n\nPivirotto\n \nP\n\n, \n\n\n \nClinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys\n. \nHum Gene Ther\n. \n2009\n;\n20\n(\n5\n):\n497\n\u2013\n510\n.\n10.1089\/hum.2008.13719203243"},{"issue":"2","key":"b69","series-title":"Neurobiol Dis","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.nbd.2011.10.004","article-title":"Glial-derived neurotrophic factor gene transfer for Parkinson\u2019s disease: anterograde distribution of AAV2 vectors in the primate brain","volume":"48","author":"Kells\n \nAP","year":"2012","unstructured":"Kells\n \nAP\n\n, \n\nForsayeth\n \nJ\n\n, \n\nBankiewicz\n \nKS\n\n\n. \nGlial-derived neurotrophic factor gene transfer for Parkinson\u2019s disease: anterograde distribution of AAV2 vectors in the primate brain\n. \nNeurobiol Dis\n. \n2012\n;\n48\n(\n2\n):\n228\n\u2013\n235\n.\n10.1016\/j.nbd.2011.10.00422019719"},{"issue":"1","key":"b70","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1212\/WNL.0b013e3181e620ae","article-title":"Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency","volume":"75","author":"Brun\n \nL","year":"2010","unstructured":"Brun\n \nL\n\n, \n\nNgu\n \nLH\n\n, \n\nKeng\n \nWT\n\n, \n\n\n \nClinical and biochemical features of aromatic L-amino acid decarboxylase deficiency\n. \nNeurology\n. \n2010\n;\n75\n(\n1\n):\n64\n\u2013\n71\n. \nPublished correction in Neurology. 2010;75(6):576\n.\n10.1212\/WNL.0b013e3181e620ae20505134"},{"issue":"134","key":"b71","series-title":"Sci Transl Med","doi-asserted-by":"publisher","first-page":"134ra61","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency","volume":"4","author":"Hwu\n \nWL","year":"2012","unstructured":"Hwu\n \nWL\n\n, \n\nMuramatsu\n \nS\n\n, \n\nTseng\n \nSH\n\n, \n\n\n \nGene therapy for aromatic L-amino acid decarboxylase deficiency\n. \nSci Transl Med\n. \n2012\n;\n4\n(\n134\n):\n134ra61\n.\n2259317410.1126\/scitranslmed.3003640"},{"issue":"4","key":"b72","series-title":"Lancet Child Adolesc Health","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","article-title":"Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial","volume":"1","author":"Chien\n \nYH","year":"2017","unstructured":"Chien\n \nYH\n\n, \n\nLee\n \nNC\n\n, \n\nTseng\n \nSH\n\n, \n\n\n \nEfficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial\n. \nLancet Child Adolesc Health\n. \n2017\n;\n1\n(\n4\n):\n265\n\u2013\n273\n.\n3016918210.1016\/S2352-4642(17)30125-6"},{"issue":"2","key":"b73","series-title":"Hum Gene Ther","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1089\/hum.2011.162","article-title":"Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum","volume":"23","author":"San Sebastian\n \nW","year":"2012","unstructured":"San Sebastian\n \nW\n\n, \n\nRichardson\n \nRM\n\n, \n\nKells\n \nAP\n\n, \n\n\n \nSafety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum\n. \nHum Gene Ther\n. \n2012\n;\n23\n(\n2\n):\n210\n\u2013\n217\n.\n10.1089\/hum.2011.16222017504"},{"issue":"4","key":"b74","series-title":"Ann Neurol","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ana.20444","article-title":"Convection perfusion of glucocerebrosidase for neuronopathic Gaucher\u2019s disease","volume":"57","author":"Lonser\n \nRR","year":"2005","unstructured":"Lonser\n \nRR\n\n, \n\nWalbridge\n \nS\n\n, \n\nMurray\n \nGJ\n\n, \n\n\n \nConvection perfusion of glucocerebrosidase for neuronopathic Gaucher\u2019s disease\n. \nAnn Neurol\n. \n2005\n;\n57\n(\n4\n):\n542\n\u2013\n548\n.\n1578647410.1002\/ana.20444"},{"issue":"4","key":"b75","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1212\/01.wnl.0000247744.10990.e6","article-title":"Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease","volume":"68","author":"Lonser\n \nRR","year":"2007","unstructured":"Lonser\n \nRR\n\n, \n\nSchiffman\n \nR\n\n, \n\nRobison\n \nRA\n\n, \n\n\n \nImage-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease\n. \nNeurology\n. \n2007\n;\n68\n(\n4\n):\n254\n\u2013\n261\n.\n10.1212\/01.wnl.0000247744.10990.e617065591"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/134\/6\/article-p1751.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/134\/6\/article-p1751.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/134\/6\/article-p1751.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:52:29Z","timestamp":1792803149000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/134\/6\/article-p1751.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":75,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2020.4.jns20701","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}